View clinical trials related to Growth Hormone Deficiency.
Filter by:The Norditropin National Registry is a post-marketing registry of patients using Norditropin therapy. A large body of data will be generated to meet the following Registry Objectives: - To develop a pharmacodynamic model defining the relationship of Norditropin dose to IGF changes, accounting for effects of known or suspected independent variables such as age, gender and puberty - To develop a model defining the relationship of GH dose and IGF exposure to treatment outcomes, accounting for effects of known or suspected independent variables such as age, gender and puberty - To develop a safety model that related GH doses to adverse even occurrence, again accounting for the effects of known or suspected independent variables - To determine the relative predictive values of pre-treatment GH stimulation tests and pre-treatment IGF-I and IGFBP-3 levels